Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Current Deferred Revenue across 15 years of filings, most recently posting $1.5 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $1.5 million, down 18.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 18.04% YoY), and the FY2025 annual result was $1.1 million, down 45.52% from the prior year.
• Current Deferred Revenue came in at $1.5 million for Q1 2026 at Ironwood Pharmaceuticals, up from $1.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $2.6 million in Q4 2023 to a low of $978000.0 in Q2 2025.
• The 4-year median for Current Deferred Revenue is $1.5 million (2026), against an average of $1.6 million.
• Across the five-year window, Current Deferred Revenue slumped 45.52% in 2025 and slipped 18.04% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Current Deferred Revenue stood at $2.6 million in 2023, then declined by 22.44% to $2.0 million in 2024, then slumped by 45.52% to $1.1 million in 2025, then jumped by 32.97% to $1.5 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.5 million (Q1 2026), $1.1 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.